Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 5
---
    $8,937,852  
     -  
    $-  
        -  
    $  -  
     145,318  
    $ 15  
    $53,899,871  
    $(2,000,000) 
    $(63,185,641) 
    $(2,347,903)
  
    Issuance of Series B shares sold to investors 
     -  
     -  
     626  
     500,000  
     -  
     -  
     -  
     -  
     -  
     (500,000) 
     -  
     - 
  
    Stock-based compensation 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     96,289  
     -  
     -  
     96,289 
  
    Net loss 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     (1,727,483) 
     (1,727,483)
  
    Balance at March 31, 2024 (Successor) 
     10,089  
    $8,937,852  
     626  
    $500,000  
     -  
    $-  
     145,318  
    $15  
    $53,996,160  
    $(2,500,000) 
    $(64,913,124) 
    $(3,979,097)

    Convertible Preferred Stock  

    Additional  
       
    Total 

    Series Seed  
    Series A  
    Common Stock  
    Paid-in  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 
  
    Balance at December 31, 2023 (Predecessor) 
     5,155,703